Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Pegylated liposomal doxorubicin
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Pharmacotherapy
The First People's Hospital of Lianyungang
Diabetes Mellitus, Type 2
1 trial -
Pramipexole
The First People's Hospital of Lianyungang
Restless Legs Syndrome
1 trial -
Prothrombin Complex Concentrate, Human
The First People's Hospital of Lianyungang
Cardiac Surgical Procedures
1 trial -
Raltitrexed
The First People's Hospital of Lianyungang
Head and Neck Squamous Cell Carcinoma
1 trial -
Realgar-Indigo Naturalis Formulation Combined with Anlotinib
The First People's Hospital of Lianyungang
Platinum-resistant Ovarian Cancer (PROC)
1 trial -
Recaticimab
The First People's Hospital of Lianyungang
STEMI - ST Elevation Myocardial Infarction
1 trial -
Recaticimab and Statin
The First People's Hospital of Lianyungang
Intracranial Atherosclerosis
1 trial -
Recombinant Human Adenovirus Type 5 injection
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma
1 trial -
Recombinant Staphylokinase
The First People's Hospital of Lianyungang
Acute Myocardial Infarction
1 trial -
Recombinant Staphylokinase
The First People's Hospital of Lianyungang
ST-segment Elevation Myocardial Infarction (STEMI)
1 trial -
Recombinant staphylokinase
The First People's Hospital of Lianyungang
ST Elevation Myocardial Infarction
1 trial -
Remimazolam Besylate for Injection
The First People's Hospital of Lianyungang
Thoracic Surgery
1 trial -
Resveratrol
The First People's Hospital of Lianyungang
Pancreatitis, Acute
1 trial -
Rifaximin
The First People's Hospital of Lianyungang
IBS - Irritable Bowel Syndrome
1 trial -
Rituximab
The First People's Hospital of Lianyungang
Hemophagocytic Lymphohistiocytosis
1 trial -
Ropivacaine
The First People's Hospital of Lianyungang
End Stage Renal Disease (ESRD)
1 trial -
Ropivacaine
The First People's Hospital of Lianyungang
Radius Fractures
1 trial -
Rosuvastatin
The First People's Hospital of Lianyungang
Hyperlipidemia
1 trial -
Rucacuzumab plus standard therapy
The First People's Hospital of Lianyungang
Acute Ischemic Stroke AIS
1 trial -
Ruxolitinib
The First People's Hospital of Lianyungang
Safety and Efficacy
2 trials -
S-1
The First People's Hospital of Lianyungang
Pancreatic Cancer
1 trial -
S-ketamine & Ropivacaine
The First People's Hospital of Lianyungang
Postoperative Analgesia
1 trial -
SGLT2 inhibitor
The First People's Hospital of Lianyungang
Type2 Diabetes
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources